Total Confirmed Cases and Deaths

<table>
<thead>
<tr>
<th>Worldwide</th>
<th>ASEAN+3</th>
<th>Plus-3</th>
<th>ASEAN</th>
</tr>
</thead>
<tbody>
<tr>
<td>187,238,474 Cases</td>
<td>6,690,106 Cases</td>
<td>1,096,936 Cases</td>
<td>5,593,170 Cases</td>
</tr>
<tr>
<td>4,038,886 Deaths</td>
<td>129,239 Deaths</td>
<td>21,799 Deaths</td>
<td>107,440 Deaths</td>
</tr>
</tbody>
</table>

Source: Haver Analytics, sourced from Johns Hopkins University; and AMRO staff calculations.

Recent Developments

Global News

- Daily confirmed cases in the US breached 20,000 for the first time since end-May 2021. The increase has been attributed to the Delta variant, present in 82 percent of cases.
- UK reported more than 34,000 daily cases in the past week, the highest since end-Jan 2021. A full economic reopening scheduled for July 19th, remains in place.
- Australia has a “firm commitment” to launch a quarantine-free travel bubble with Singapore, now likely to occur by year-end due to Sydney’s outbreak.

Regional News

- Malaysia has closed a COVID-19 vaccination centre after more than 200 volunteers and workers at the centre tested positive. Average daily cases surpassed previous peak to reach more than 8,500 cases in the last week.
- Indonesia is expanding healthcare capacity, boosting vaccination drive and curbing mobility after cases and deaths rose to record highs. Frontline workers who have been fully vaccinated with Sinovac vaccine will receive a booster shot of Moderna vaccine.
- Daily cases in Korea reached all-time high, due to the highly contagious Delta variant. Vaccination roll-out was halted when strong demand crashed the booking website.

Vaccine News

- WHO has discouraged developed economies from ordering vaccine boosters, which would widen an already highly uneven and inequitable global supply gap.
- US FDA has issued an advisory on Johnson & Johnson vaccine after a small number of the rare autoimmune disorder, Guillain-Barré, were reported post-vaccination.
- A Japanese firm, Daiichi Sankyo, will begin Phase 3 clinical trials for its mRNA COVID-19 vaccine with plans for it to be available for use by 2022. Three other local companies are also conducting vaccine trials.
ASEAN+3 and Selected Economies: Confirmed COVID-19 Cases and Deaths

Source: Haver Analytics, sourced from Johns Hopkins University; and AMRO staff calculations.

1/ Values show the 7-day average.

ASEAN+3 and Selected Economies: Total Vaccines Administered

ASEAN+3 and Selected Economies: Vaccinations and Aspired Population Coverage

Source: Haver Analytics, sourced from Our World in Data; and AMRO staff calculations.
Note: Single vaccination doses only. This does not measure the number of people vaccinated, as two doses are required with most available vaccines. Data is reported at irregular intervals; numbers show latest available.